AstraZeneca PLC (LON:AZN – Get Free Report) shares reached a new 52-week high during trading on Tuesday . The company traded as high as £151.98 and last traded at £150.74, with a volume of 2093291 shares changing hands. The stock had previously closed at £151.23.
• 5 Oversold Stocks to Buy Right Now
AZN has been the topic of several research analyst reports. Citigroup initiated coverage on AstraZeneca in a research note on Tuesday, January 27th. They set a “buy” rating and a £170 target price on the stock. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a report on Thursday, January 15th. Berenberg Bank upped their price objective on shares of AstraZeneca from £145 to £160 and gave the stock a “buy” rating in a report on Tuesday, January 27th. Jefferies Financial Group reaffirmed a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. Finally, Shore Capital Group reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of £145.83.
Get Our Latest Analysis on AstraZeneca
• 20 best healthcare dividend stocks to invest in
The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93. The business’s 50-day moving average is £138.67 and its 200-day moving average is £128.92. The company has a market capitalization of £233.69 billion, a PE ratio of 25.04, a PEG ratio of 0.86 and a beta of 0.17.
In related news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.15% of the stock is currently owned by corporate insiders.
• 3 stocks that crushed earnings estimates and still tanked
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
• Five stocks we like better than AstraZeneca
• Your Bank Account Is No Longer Safe
• Buy this Gold Stock Before May 2026
• What a Former CIA Agent Knows About the Coming Collapse
• This $15 Stock Could Go Down as the #1 Stock of 2026
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in AstraZeneca Right Now?
Before you consider AstraZeneca, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and AstraZeneca wasn’t on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here…Read more by MarketBeat